Company research / KYMR

Kymera Therapeutics, Inc. (KYMR)

CIK 0001815442 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Kymera Therapeutics, Inc. reported revenue of $39.21M. Revenue fell 16.7% from the prior annual period.

Key ratios (year ended 2025-12-31)

-891.1%
Operating margin
-794.0%
Net margin
-19.7%
Return on year-end equity
-16.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-04

Headquarters locality: Watertown · View on map

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.